Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Neuroscience 9, 252–253 (1 April 2008) | doi:10.1038/nrn2362
Psychiatric disorders: Double GPCR trouble
Abstract
Glutamatergic and serotoninergic systems have been implicated in psychotic disorders. Gonz|[aacute]|lez-Maeso and colleagues, writing in Nature, show that 5-hydroxytryptamine (5-HT) 2A receptors (5-HT2AR) — through which many existing antipsychotic drugs act — and metabotropic type-2 glutamate receptors (mGluR2) — which are potential new anti-psychotic targets — form complexes that might be involved in schizophrenia.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
